CG MedTech to develop bioresorbable magnesium vascular stent

CG MedTech, a Korea-based orthopedic implant company specializing in magnesium alloy technology, said it has entered full-scale development of a next-generation bioresorbable vascular stent that naturally degrades inside the body after fulfilling its intended function.

Unlike traditional permanent metal stents, which remain in the body indefinitely after implantation, the company’s new stent—built using a proprietary magnesium alloy—gradually dissolves and is absorbed by the body.

The innovation is gaining attention as a potential alternative for vascular disease treatment, especially amid growing demand for safer and more adaptable solutions in aging societies.

The magnesium-based stent performs the same blood vessel expansion function as conventional metal stents but is designed to break down over time, eliminating long-term foreign body presence.

This significantly reduces the risk of thrombosis and other chronic complications, while improving overall biocompatibility due to magnesium’s low inflammatory response compared to conventional metals.

Also, the use of bioresorbable materials may allow for shorter durations of antiplatelet therapy and lower the incidence of late-stage adverse effects. These advantages are expected to lessen the treatment burden on patients and improve long-term quality of life, offering a new paradigm in the treatment of cardiovascular and peripheral vascular diseases.

The development is part of a national R&D project supported by Korea’s Ministry of Science and ICT and supervised by the National Research Foundation of Korea. The five-year initiative, launched in 2022 and running through 2026, is led by the Korea Institute of Science and Technology (KIST). CG MedTech has now entered the product optimization and commercialization phase of the project.

CG MedTech has already proven the safety and technical feasibility of its proprietary magnesium technology through the successful commercialization of bioresorbable orthopedic screws and plates.

These implants maintain high mechanical strength while gradually decomposing inside the body—a feature that could enable wider applications in next-generation implantable medical devices.

According to market research firm Business Research Insights, the global cardiovascular stent market is projected to reach $20.67 billion by 2032, with the peripheral vascular stent segment expected to grow to $7.82 billion.

“The bioresorbable vascular stent represents a breakthrough that addresses the limitations of permanent metal stents, while prioritizing both safety and convenience for patients,” CG MedTech CEO Yu Hyun-seung said. “We aim to become a global healthcare partner by advancing world-class magnesium-based biodegradable medical device technology to improve the quality of life for patients worldwide.”